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Nearly half of the people suffering from schizophrenia also
present with a lifetime history of substance use disorders
(SUD), a rate that is much higher than the one seen among
unaffected individuals. This phenomenon suggests that the
factors inﬂuencing SUD risk in schizophrenia may be more
numerous and/or complex than those modulating SUD risk
in the general population. It is critically important to
address this comorbidity because SUD in schizophrenic
patients is associated with poorer clinical outcomes and
contributes signiﬁcantly to their morbidity and mortality.
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Nearly half of the people suffering from schizophrenia
also present with a lifetime history of substance use dis-
orders (SUDs).
1,2 This rate is much higher than the one
seen in the general US population (table 1 provides prev-
alence estimates for the most frequently abused substan-
ces in schizophrenia patients compared with the general
population),
11,12 which suggests that in addition to fac-
tors driving SUD in the general population, other factors
are increasing the risk in schizophrenia. Addressing
comorbidity is clinically relevant because SUD in schizo-
phrenic patients is associated with poorer clinical
outcomes
18 and contributes significantly to their morbid-
ity and mortality.
19
The mechanisms underlying the high comorbidity be-
tween SUDand schizophreniaare poorly understoodbut
are likely to include both common (across all drugs) as
well as drug-specific (eg, nicotine and marijuana) factors.
The involvement of brain dopaminergic pathways is
likely to be a shared feature in this comorbidity that is
common to all drugs of abuse. To start with, the meso-
limbic dopamine (DA) pathway has been implicated not
only in the rewarding mechanism for all drugs of abuse
(via DA increases in nucleus accumbens or NAcc) but
also in the occurrence of positive symptoms in schizo-
phrenia (via excess striatal DA). Thus, it is not surprising
that drug intoxication (from cocaine, methamphetamine,
or marijuana use) can trigger acute psychotic episodes
and that some drugs (amphetamines) have been used
to create surrogate animal models of schizophrenia.
On the other hand, the mesocortical DA pathway has
been implicated in the neuroadaptations that result
fromrepeateddrugexposures(viaDAdeficitsinprefron-
tal regions)
20 and as a contributor to the negative symp-
toms of schizophrenia (via decreased DA in prefrontal
cortex). Most antipsychotic medications block DA D2
receptors (D2Rs), thus interfering with DA neurotrans-
mission. Therefore, it is conceivable that schizophrenia
patientsmayresorttodrugsofabusetotemporarilycom-
pensate for the anhedonia induced by D2R blockade in
brain regions involved with reward (NAcc and ventral
pallidum)and/orcounteractthe cognitivedeficits(eg,im-
paired attention, working memory) that result from pre-
frontal D2R blockade. However, because chronic drug
use is associated with reduced DA neurotransmission,
this behavior could actually backfire and exacerbate neg-
ative symptoms and cognitive deficits (eg, attention, ex-
ecutive function, saliency) and interfere with functional
recovery.
21
The comorbidity of SUD and schizophrenia may also
be a direct consequence of the underlying neuropathol-
ogy of schizophrenia, which may contribute to enhanced
addiction vulnerability by disrupting the neural sub-
strates that mediate positive reinforcement.
22 One pro-
posal is that an imbalance of hippocampal-prefrontal
regulation of DA release in NAcc may contribute to
both psychosis and the vulnerability to drug abuse in
schizophrenia. Non-DA pathways have been implicated
too. For example, the cognitive impairments associated
with prefrontal circuits also involve dysregulated gluta-
matergic neurotransmission, and for both disorders,
medications that affect glutamatergic neurotransmission
are being evaluated as potential treatments.
23
Nicotine is by far the most prevalent drug abused by
schizophrenia patients. While this may be partly due
to its legal status and easy access, it may also reflect nic-
otine’s specific effects on brain nicotinic acetylcholine
receptors (nAChRs). The ‘‘self-medication hypothesis’’
suggeststhat smokingmayalleviate someofthe cognitive
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be a neural basis for this hypothesis: specifically, it has
been reported that individuals with schizophrenia have
fewer and less functional, low-affinity and high-affinity
nicotine receptors. This might explain how smoking by
schizophrenia patients could improve some of the cogni-
tive deficits seen in this disorder.
24 Postmortem studies
have also reported that the brains of schizophrenia
patients have deficits in inhibitory neurons. Thus, the
recent findings showing that nicotine upregulated the
expression of the glutamic acid decarboxylase gene, in-
creasingc-aminobutyricacidsynthesis inthebrain, could
be another pharmacological effect that contributes to
comorbidity.
Cannabis is also frequently abused by schizophrenic
patients, and it is associated with worse clinical out-
comes. For example, a recent magnetic resonance im-
aging study concluded that the loss of gray matter,
commonly seen in the brains of schizophrenic patients,
proceeds nearly twice as fast in patients who also used
cannabis over a 5-year follow-up. Because the differ-
ence could not be explained by outcome or baseline
characteristics, this result adds to the evidence in favor
of a detrimental effect of cannabis in schizophrenia.
Just as for other drugs, it is possible that schizophrenic
patients abuse marijuana not only for its hedonic prop-
erties but also for other pharmacological effects of can-
nabinoids. Specifically, because a basic function of the
endocannabinoid system in the brain is to control emo-
tional responses to stress,
25 it is plausible that some
schizophrenic patients may abuse marijuana to help
them cope with stress. Though there is evidence of alter-
ations in cannabinoid signaling in the brain of schizo-
phrenic patients,
26 their role in the neuropathology of
schizophrenia is still poorly understood. It is also still un-
clear if marijuana abuse constitutes a risk factor for
schizophrenia that by itself has a causative role and/or
if it just serves to trigger the disease in those who are vul-
nerable. In this respect, the role of marijuana on schizo-
phrenia is a good example of the importance of gene/
environment interactions in psychiatric diseases.
Genetic and gene/environment factors that contribute
to schizophrenia may also contribute to addiction. Both
schizophrenia and addiction are highly heritable and ge-
netically complex disorders, and, even though studies are
still struggling with small effect sizes and inconsistencies,
the field appears to be coalescing around a select, albeit
by no means controversy-free set of candidate genes.
These include convergent findings, from genetic risk
data, which suggest that individual differences in the
quality and quantity of brain connections, during devel-
opmentand/orinadulthood,contributetoindividualdif-
ferences in vulnerability to addictions and to related
brain disorders like schizophrenia.
27 Other findings point
to overlaps between the genes identified in schizophrenia
and some of the genes identified in addiction. These in-
clude genes involved in neuroplasticity and brain devel-
opment, such as Neuregulin 1 (NRG1) and members of
the neurexin family (NRXN 1 and 3) genes that code
for molecular targets of drugs such as the a7nAChRs,
and genes that modulate the activity of DA and other
catecholamines, such as catechol-O-methyltransferase,
Table 1. Schizophrenia Patients Report Consistently Higher Rates of Substance Abuse Than the General Population, Notably With
Respect to 4 Licit (Nicotine and Alcohol) and Illicit (Cannabis and Cocaine) Substances
Abused
Substance
Schizophrenia Patients General Adult Population
Reported Rate of
Use (Range From
Various Studies)
Reported DSM-IV
Abuse or Dependence
(Range From Various
Studies)
Rate of Use
(Past month for ages
18 or older) (NSUDH)
(SAMHSA 2008)
DSM-IV
Dependence
in Past Year
Nicotine 60%–90%
3–5a 28.5%
6b 25.9% 12.8%
7
Cannabis 17%–80.3%
8–10c 50.8%
8 5.8%–16.4% 0.5%
11,12
Alcohol 21%–86%
8,13–15d 43.1%–65%
8,16 2.9%–17.9%
e 5.1%
11,12
Cocaine — 23%
16 0.7%–1.7% 0.09%
11,12f
Note: Prevalence ranges are merely intended to illustrate the consistency of the trend in this population because they represent diverse
sampling methods among studies done with different adult populations and measures of abuse. The average rates of use and abuse or
dependence in the general adult population were derived from the 2007 National Survey on Drug Use and Health
17 and secondary
analyses of the 2000–2002 National Epidemiologic Survey on Alcohol and Related Conditions
11,12 and are not intended to provide control
baselines but as expedient markers for general comparison. DSM-IV, Diagnostic and Statistical Manual of Mental Disorders (Fourth
Edition); NSUDH, National Survey on Drug Use & health; SAMHSA, Substance Abuse and Mental Health Services Administration.
aCurrent daily smokers.
bBased on a calculated odds ratio of 2.8 higher than in controls.
cPast month.
dAlcohol misuse, abuse, or disorder.
eHeavy use.
fStimulants.
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470V-akt murine thymoma viral oncogene homolog 1
(AKT1), and Monoamine oxidase A (MAOA).
Common psychosocial factors (eg, limited education,
poverty,unemployment,peerinfluence,andthestructure
of the mental health treatment system) may account for
a portion of the increased comorbidity. Both disorders
are associated with a greater exposure to stressors, which
on one hand increase drug taking and on the other exac-
erbate psychotic symptoms in schizophrenia patients.
28
Thus, prevention interventions that mitigate the adverse
effects of social stress on individuals at risk for schizo-
phrenia may also help curb drug use in this population.
Finally, concurrent drug abuse is recognized to signif-
icantly contribute to the morbidity and mortality in
schizophreniapatients.Thisincludesthedevastatingcon-
sequencesfromheavysmokinginthispatientpopulation,
aswellasdeathsfromoverdoseandpoisoningfromother
drugs ofabuse.
19Moreover, because somedrugs of abuse
target mechanisms implicated in the metabolic syndrome
(ie, marijuana targeting the cannabinoid receptor), one
could speculate that they may also exacerbate this side
effect of antipsychotic medications.
Despite its importance, research on the treatment of
comorbidity has been very limited. Nonetheless, some
promising findings have been reported. This includes
a recent study that focuses on the known disturbances
in the endocannabinoid system of schizophrenics and
points to anandamide as a promising target for medica-
tions to reduce substance abuse in schizophrenia
patients. Similarly, some studies suggest that some sec-
ond-generation antipsychotics may be effective for
comorbid SUD in schizophrenia, particularly clozapine
and nicotine dependence. Of the behavioral interven-
tions that have been evaluated, assertive community
treatments, which integrate the behavioral treatment
of severe mental disorders, such as schizophrenia, and
co-occurring SUD, is a promising example. There is
also a need for services research that focuses on the spe-
cial treatment challenges in patients with comorbid
schizophrenia and SUD, such as the implementation
of therapeutic interventions in criminal justice settings,
where persons suffering from severe mental illness and
SUDs are markedly overrepresented.
In summary, addressing comorbidity of SUD in
schizophrenia has important clinical implications for
both the prevention and treatment of these 2 disorders
and also for decreasing morbidity and mortality. More-
over, research shows that treatment of patients with
comorbidity should include interventions for both disor-
ders because lack of adequate treatment of one of the dis-
orders interferes with recovery.
29 These reasons highlight
the urgency of addressing the need for integrated treat-
ment interventions for SUD in patients with schizophre-
nia and for training psychiatrists in the proper screening
and treatment of SUD in patients with schizophrenia and
other mental illnesses.
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